Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
ORIGIN
ORIGIN IgAN Study
Breve descripción
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.
Médico del ensayo/Coordinador del estudio
Jean Damascène Barahira
Correo electrónico
Número de teléfono
(324) 366-7405
Nombre del sitio
Centre Hospitalier Universitaire (CHU) de Liege
Centre Hospitalier Universitaire (CHU) de Liege Tour 1, 6 eme etage, Boulevard de l'hopital B35 Liège, Belgium 4000
Nombre del patrocinador
Vera Therapeutics
Nombre del fármaco del estudio
atacicept
Matrícula estimada
105 participants
Fecha estimada de finalización
The estimated end date of enrollment of the study is in the second quarter of 2022
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
ORIGIN
ORIGIN IgAN Study
Breve descripción
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.
El ensayo es para personas con
A diagnosis of IgAN confirmed by a kidney biopsy with the past 10 years who are on a stable, prescribed regimen of an RAASi (for example, ACE/ARB) medication for at least 12 weeks.
Qué implica para el paciente?
Complete assessment like physical exams, blood tests and 24 hour urine. Patients will be assigned to receive active study medication or placebo. There is a 70% chance of being assigned to receive active study mediation. Receive once-weekly injections (at the clinic or at home). Attend clinic visits over the course of 9 months. After completing the 9 months all participants will be able to receive active study medication for an additional 60 weeks.
Sobre el medicamento o la intervención
Atacicept is designed to help prevent the buildup of IgA in the kidneys by controlling the immune response that causes IgAN.
